간행물

생화학분자생물학회입니다.


EMM

The roles and mechanisms of coding and noncoding RNA variations in cancer

  • 작성자

    Suk Woo Nam
  • 작성일자

    2024-12-26
  • 조회수

    382
Suk Woo Nam ( swnam@catholic.ac.kr )
2003-presentProfessor, Department of Pathology, The Catholic University of Korea, Republic of Korea
2014-presentDirector, Functional RNA Research Center,  The Catholic University of Korea, Republic of Korea
2001-2002Research Associate, Genome Institute of Singapore, Singapore 
1997-2001Post-doctoral fellow, Lab of Pathology, National Cancer Institute, National Institute of Health, Bethesda, MD, USA
1991-1997Ph.D. Pharmacist, Sungkyunkwan University,  College of Pharmacy, Seoul, Republic of Korea

The roles and mechanisms of coding and noncoding RNA variations in cancer

Functional variations in coding and noncoding RNAs are crucial in tumorigenesis, with cancer-specific alterations often resulting from chemical modifications and posttranscriptional processes mediated by enzymes. These RNA variations have been linked to tumor cell proliferation, growth, metastasis, and drug resistance and are valuable for identifying diagnostic or prognostic cancer biomarkers. The diversity of posttranscriptional RNA modifications, such as splicing, polyadenylation, methylation, and editing, is particularly significant due to their prevalence and impact on cancer progression. Additionally, other modifications, including RNA acetylation, circularization, miRNA isomerization, and pseudouridination, are recognized as key contributors to cancer development. Understanding the mechanisms underlying these RNA modifications in cancer can enhance our knowledge of cancer biology and facilitate the development of innovative therapeutic strategies. Targeting these RNA modifications and their regulatory enzymes may pave the way for novel RNA-based therapies, enabling tailored interventions for specific cancer subtypes. This review provides a comprehensive overview of the roles and mechanisms of various coding and noncoding RNA modifications in cancer progression and highlights recent advancements in RNA-based therapeutic applications.

Exp Mol Med. 2024 Sep;56(9):1909-1920. doi: 10.1038/s12276-024-01307-x
https://pubmed.ncbi.nlm.nih.gov/39218979/